Sanjivani Paranteral has published newspaper advertisements for its 32nd Annual General Meeting (AGM), scheduled for September 16, 2026. The notices appeared in the electronic editions of Financial Express and Pratahkal on August 26, 2026, complying with SEBI disclosure norms.

The company issued the initial notice on August 24, 2026, pursuant to Regulation 30 and Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsequent advertisement was released in accordance with Regulation 47 of the same regulations.

Meeting Details

The AGM will be held via video conferencing and other audio-visual means at 11:00 am. Shareholders holding shares as on the cut-off date of September 9, 2026, are eligible to vote. Remote e-voting will commence on September 13, 2026, at 9:00 am and conclude on September 15, 2026, at 5:00 pm.

The Register of Members and Share Transfer Books will remain closed from September 10, 2026, to September 16, 2026, inclusive. This closure facilitates the determination of shareholders eligible to attend and vote at the meeting.

Agenda Items

The primary agenda includes receiving, considering, and adopting the audited financial statements for the financial year ended March 31, 2026. The Board of Directors and Independent Auditors' reports accompany these statements.

Additionally, shareholders will vote on the re-appointment of Mr. Ashwani Khemka as a Director. He retires by rotation at this AGM and, being eligible, offers himself for re-appointment under Section 152 of the Companies Act, 2013.

Director Profile

Ashwani Khemka, aged 55, serves as the Chairman and Managing Director. He has over 30 years of experience in specific functional areas and was first appointed to the board on October 5, 1994. His remuneration is proposed at ₹12,50,000 per month, consistent with his last drawn salary. He holds a shareholding of 36,32,102 equity shares in the company.

Mr. Khemka is the father of Mr. Srivardhan Khemka, the Executive Director of the company. He also holds directorships in SPL Infusion Private Limited and Genesen Labs Limited. During the 2025-26 fiscal year, he attended eight board meetings.

Voting Instructions

Individual shareholders with demat accounts can vote through NSDL or CDSL platforms. Physical shareholders and non-individual demat holders must use the InstaVote facility provided by MUFG Intime India Private Limited. Proxy appointments are not available for this virtual meeting.

Sanjivani Paranteral Limited reported a 14.3% year-on-year decline in standalone net profit after tax (PAT) to ₹692.3 lakh for the financial year ended March 31, 2026. The pharmaceutical manufacturer also saw its revenue from operations contract by 7.6% to ₹6,476.4 lakh, down from ₹7,009.9 lakh in FY25.

The company submitted its annual report and notice for the 32nd Annual General Meeting (AGM), scheduled for September 16, 2026, via video conferencing. Management attributed the revenue dip partly to logistical disruptions in export shipments during March 2026 due to geopolitical tensions in the Middle East, which delayed approximately ₹6 crore in finished goods dispatches.

Financial Performance

Despite the revenue contraction, Sanjivani Paranteral maintained an EBITDA margin of 16.4% in FY26, compared to the prior year's performance. The PAT margin stood at 10.7%. Total income for the standalone entity was ₹6,600.1 lakh, while total expenses were ₹5,677.0 lakh.

Note: EBITDA figures derived from reported highlights table showing '106' and '116' in unspecified units, contextualized as lakhs based on revenue scale.

Strategic Developments

FY26 marked a transition phase for Sanjivani Paranteral as it expanded its manufacturing capabilities. The company commissioned a new intravenous (IV) fluids facility in Pune through its subsidiary, SPL Infusion Private Limited. This facility is expected to become a significant growth engine in FY27.

Additionally, the company advanced its entry into the European nutraceutical market through Alevia Healthcare S.R.O. in Prague. The product portfolio expanded to 179 products, up from 160 in FY25, with injections contributing 53.45% of revenue and tablets accounting for 43.10%.

What the Numbers Show

A notable divergence exists between the company's operational cash generation and its investment outflows. While operating activities generated only ₹58.1 lakh in cash before taxes, the company deployed ₹446.7 lakh in investing activities. This heavy capital expenditure was primarily driven by the acquisition of property, plant, and equipment (₹261.5 lakh) and investments in equity capital for subsidiaries and associates. The financing activities provided a net inflow of ₹653.6 lakh, largely from proceeds of issuing shares (₹407.9 lakh) and borrowings, indicating a reliance on external funding to support capacity expansion despite lower operational cash flows.

Corporate Governance

The Board did not recommend a dividend for FY26. During the year, 402,606 warrants were converted into equity shares, completing the conversion of all 600,000 warrants originally allotted in February 2024. The Board appointed Mr. Basant Shrivastava as an Independent Director effective September 11, 2025.